CSU Animal Cancer Center Clinical Trial
Cachexia (May be associated with any neoplasm, except those located within the GI tract)
Melanocortin 4 Receptor Antagonist in the Treatment of Canine Cachexia
Purpose of the study:
- To evaluate effectiveness of a novel therapeutic to increase the body weight and quality of life in dogs experiencing cachexia (weight loss).
Primary Eligibility Criteria:
- Clinical diagnosis of cachexia- at least 5% loss of body weight in the past 3 months, not reversed by increasing intake of food.
- Initial screening to determine eligibility (physical exam, lab work).
- Abdominal ultrasound, blood pressure check, 24-hour Holter monitor.
- Medication administration begins once cardiac status is approved by a cardiologist.
- Medications are given once daily as an injection under the skin (SQ). There are rechecks at CSU weekly.
- The Holter monitor (for 24 hours); is repeated at day 28.
- The clinical trial lasts for 28 days. There is the option to continue the medication off trial which can be discussed at the end of the trial.
- To administer medications as prescribed. You must be comfortable giving daily injections.
- To make and keep all appointments for the study protocol.
- Study pays for study procedures (exams, diagnostic testing, and study medication once enrolled in the trial).